Scientist - Oncology Diagnostics / Liquid Biopsy
Salary £37,000 - £45,000 (commensurate with experience)
Do you have experience in the development of molecular IVD technology?
Would you like to contribute to the invention of the next generation of oncology diagnostics technology?
Our client, the inventors of semiconductor-based next-generation sequencing (NGS) technology, is developing a revolutionary new platform that enables NGS-based diagnostic capability in an easy to use, cartridge-based system that will allow direct from clinical specimen to clinically relevant, actionable results in a matter of hours. They are now looking to add to their multidisciplinary team an experienced research and development scientist, to focus on new applications for their existing technology platform.
The Scientist - Oncology Diagnostics / Liquid Biopsy will be part of the New Application Research Team and will be responsible for novel oncology NGS library preparation and oncology sample preparation technology development for their proprietary sequencing technology. The developed chemistry must be compatible with cartridge-based automation and performance must meet the demanding requirements of a novel NGS platform.
Specific responsibilities of the Scientist Scientist - Oncology Diagnostics / Liquid Biopsy include;
* Design and execution of laboratory experiments and in-depth analysis of resulting data
* Performing market research on competitor technologies, literature searches and technology scouting to stay up to date with current advancement in the field
* Leads specific projects/ tasks within project scopes
* Participation in the integration of the technology into the automated platform
* Generation and management of all required documentation and presentation of results
We are looking for people with drive, enthusiasm and a rock-solid work ethic who strongly desire to play a key role in the creation of a paradigm shifting platform that will have major impact on the health and well-being of patients around the world. The successful candidate must have the ability to deliver effective solutions to challenging problems in a fast-paced environment with adherence to tight timelines. Further, the successful candidate must be a team player who interacts well with a variety of colleagues within and outside their area of expertise, is a strong and proactive communicator and is willing to step in and take on additional responsibilities as they arise, even those outside the normal scope of responsibilities, in order to help achieve timely success of the project.
Qualifications and experience
* PhD (preferred) or MSc in Biochemistry, Molecular Biology, Candidate/s having experience in genomics in oncology will be given preference.
* Industry experience in the development of biotechnology/ molecular IVD technology for commercially relevant applications
* Experience in development and use of Next Generation Sequencing (NGS) workflows, with specific experience in development of novel NGS sample preparation/ library preparation chemistries/methods
* Knowledge of commercial NGS data analysis
* Demonstrable creativity and innovation (e.g., as evidenced by patent filings and allowances and/or scientific publications)
* Excellent problem solving and analytical skills
* Excellent administrative, organisational, communication and interpersonal skills.
* IVD product development experience, especially NGS-based products
* Experience developing project plans using tools such as Microsoft Project
* Experience in working in CAT2 facility
* Experience integrating assay chemistries onto automation platforms, especially cartridge-based systems; including experience stabilising key reagents for long term storage in the cartridge
Key Words "Development Scientist, IVD, PhD, Research and Development, R&D, Molecular Diagnostics, NGS, Next-Generation Sequencing, Oncology, Liquid Biopsy, London"
Please apply online or call Neil Walton on 02030964706
You must be eligible to work in the UK. Learn more
- Agency: SRG
- Reference: J33049
- Posted: 7th August 2019
- Expires: 4th September 2019